Mereo BioPharma gives Q3 2026 update on setrusumab and alvelestat regulatory talks
Mereo reported cash of $26.1 million as of September 30, 2026, with runway into late 2027, as it continues regulatory discussions on setrusumab and alvelestat.
SEC filing